InsidersTradesSigma
Track the 신신제약 stock price and the full management transaction log of the company, a publicly traded company based in South Korea. Shares are listed on the KR market, under the supervision of DART (FSS). Operating in the Health Care sector, 신신제약 has logged 26 public disclosures. Market capitalisation: €64.2bn. The latest transaction was reported on 1 July 2026 (Purchase). Among the most active insiders: 이종민. All data is accessible without an account.
26
Insider Decl.
n/a
Thresholds
n/a
4 ops.
Buy Volume
n/a
1 ops.
Sell Volume
7Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 3,690 of 29,062 companies
71.6
score / 100
Value83
Quality60
FCF yld9.7%
Earn yld13%
EV/EBITDA7.4x
ROE18%
Gross mgn38%
Net mgn8.2%
Debt/EBITDA2.8x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 1 July 2026
Declarations26 total
25 of 26 declarations
关于 신신제약
신신제약 是一家在XKRX交易所上市的医疗保健和制药公司。它专注于医药产品的开发和营销。